Zura Bio Limited (ZURA) Stock Analysis — Probabli.AI
AI-powered analysis for ZURA (Zura Bio Limited): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $4.04 · Market cap: $389.1M · AI outlook: Bullish
Zura Bio Limited (NASDAQ: ZURA) is a clinical-stage biotechnology company developing multi-target cytokine inhibitors for severe autoimmune diseases. At a market cap under $400M and a current share price of $4.04, ZURA trades at a severe discount relative to sell-side Wall Street models, where all seven covering analysts rate the company a Strong Buy with a median price target of $20.00. The…
Probabilistic 1-Year Outlook
- Bull 50% · Neutral 25% · Bear 25%
- 1-year price estimates — P10: $2 / P50: $7 / P90: $16
- Unanimous Wall Street consensus with 7 Strong Buy ratings and a median price target of $20.00 reflects significant clinical undervaluation. However, binary clinical-stage biotech risks and ongoing cash burn maintain…
5-Year Outlook
- Bull 45% · Neutral 15% · Bear 40%
- 5-year price estimates — P10: $1 / P50: $13 / P90: $38
SWOT Highlights
- Strength: Differentiated clinical pipeline focused on dual-pathway cytokine inhibition (e.g., Tibulizumab targeting IL-17A and BAFF)
- Strength: Unanimous analyst conviction with 7 Strong Buy ratings and +337% consensus upside
- Risk: Zero commercial revenue with substantial ongoing net losses (-$0.20 expected quarterly EPS)
- Risk: High dependency on external equity financing and capital markets for ongoing Phase 2 trials
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
7 Wall Street analysts rate ZURA a STRONG BUY with a mean price target of $17.67.
Last analyzed · Model: gemini-3.8-flash. How this forecast works · Accuracy & validation.
ZURA forecast details · ZURA sentiment details
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.